Evidence map›Paper›PMID 42836888›Full record

ArticleNeurogenetics2026

Genetic findings in a Turkish clinical cohort with hereditary Parkinson's disease.

Dilek Ozata Aksoy, Yusuf Tunca, Ali Riza Sonkaya, Deniz Torun, Osman Korucu

Abstract read
PubMed Publisher
In one paragraph

Article in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dilek Ozata AksoyDepartment of Medical Genetics, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Türkiye. dilekozata25@gmail.com.ORCID http://orcid.org/0009-0001-7707-4871
Yusuf TuncaDepartment of Medical Genetics, Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Türkiye.
Ali Riza SonkayaDepartment of Neurology, Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Türkiye.
Deniz TorunDepartment of Medical Genetics, Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Türkiye.
Osman KorucuDepartment of Neurology, Ataturk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeParkinson's disease (PD) is a multifactorial neurodegenerative disorder driven by a complex interplay of genetic and environmental factors. This study aimed to characterize the mutational spectrum in a cohort of patients with clinically suspected hereditary PD using complementary genetic testing approaches. MATERIALS AND

methodsA total of 36 patients underwent genetic evaluation. Targeted next-generation sequencing (NGS) of a 10-gene PD panel was performed in 35 patients, Multiplex ligation-dependent probe amplification (MLPA)-based copy-number analysis using an 8-gene panel was conducted in 9 patients, and targeted Sanger sequencing was performed in one patient with a known familial PRKN variant.

resultsThe most clinically relevant findings involved the PRKN gene. A homozygous pathogenic variant in the PRKN gene was detected in 3 patients, compound heterozygous deletions involving the PRKN and PACRG genes in one patient, and a single heterozygous PRKN variant classified as pathogenic was detected in one patient. Additionally, variants of uncertain significance were identified in 7 patients in the ATP13A2, PRKN, VPS35, PINK1, and PLA2G6 genes.

conclusionUsing complementary molecular genetic techniques, we identified clinically relevant genetic findings in a cohort of 36 patients with suspected hereditary Parkinson's disease. These findings provide population-specific data on the mutational spectrum of PD in a Turkish clinical cohort and contribute to the characterization of the regional genetic landscape.

Indexed as

Parkinson DiseaseUbiquitin-Protein LigasesAdultAgedCohort StudiesFemaleGenetic Predisposition to DiseaseGenetic TestingGroup VI Phospholipases A2HeterozygoteHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationProtein KinasesGroup VI Phospholipases A2parkin proteinPLA2G6 protein, humanProtein KinasesPTEN-Induced Putative KinaseUbiquitin-Protein LigasesVesicular Transport ProteinsVPS35 protein, humanGenetic testingHereditary Parkinson's diseaseMultiplex ligation-dependent probe amplificationNext-generation sequencingPRKN

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.